As a Free StocksGuide user, you can view scores for all 7,039 stocks worldwide.
9 Analysts have issued a Palisade Bio Inc forecast:
9 Analysts have issued a Palisade Bio Inc forecast:
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -15 -15 |
16%
16%
|
|
| EBIT (Operating Income) EBIT | -15 -15 |
16%
16%
|
|
| Net Profit | -14 -14 |
17%
17%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company is headquartered in Carlsbad, CA.
| Head office | United States |
| CEO | J. Finley |
| Employees | 8 |
| Founded | 2011 |
| Website | palisadebio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


